This is a non-randomised open-label phase 1 trial of pembrolizumab given in combination with SBRT to part of a pleural-based lesion in patients with unresectable malignant pleural mesothelioma. PI – Fiona McDonald
This is a non-randomised open-label phase 1 trial of pembrolizumab given in combination with SBRT to part of a pleural-based lesion in patients with unresectable malignant pleural mesothelioma. PI – Fiona McDonald